Global Generic Oncology Drugs Market Report and Forecast 2023-2031

Global Generic Oncology Drugs Market Report and Forecast 2023-2031


Global Generic Oncology Drugs Market Outlook


The global generic oncology drugs market value was USD 25.3 billion in 2022, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 6.2% during the forecast period of 2023-2031 to achieve a value of USD 43.7 billion by 2031.

Generic Oncology Drugs Introduction


Generic Oncology Drugs refer to the pharmaceuticals that are used to prevent, diagnose, and treat various types of cancer. These drugs are generally produced after the patent expiration of their branded counterparts, making them more affordable for patients.


The global generic oncology drugs market is witnessing significant growth due to the rising prevalence of cancer worldwide and increasing demand for cost-effective treatments. Additionally, the introduction of biosimilars in the oncology drug market is expected to drive market growth in the coming years

However, the high cost of research and development activities and the stringent regulatory policies regarding drug approval are the major factors that may hamper the growth of the market. In addition, the limited availability of oncology drugs in underdeveloped and developing countries may also restrain market growth.

Despite these challenges, the market is expected to grow significantly due to the increasing focus of key players on developing generic versions of cancer drugs and the rising demand for personalized medicine in cancer treatment. The emergence of new technologies such as precision medicine and immunotherapy is also expected to boost the market growth in the coming years.

Generic Oncology Drugs Market Scenario


Generic oncology drugs are low-cost alternatives to their brand-name counterparts, designed to treat cancer. These drugs are equivalent in terms of dosage, strength, route of administration, quality, and intended use as the innovator drugs but are sold at lower prices. These drugs are widely available in various formulations, including injectables, capsules, tablets, and liquids.


The global generic oncology drugs market is driven by factors such as increasing prevalence of cancer, patent expiry of blockbuster drugs, and rising demand for cost-effective treatment options. In addition, the advent of new technologies in drug delivery and the increasing trend of mergers and acquisitions among key players in the market are expected to create growth opportunities.

However, the stringent regulatory requirements for approval and quality control of generic drugs and the high cost of research and development of new drugs are some of the major factors that may restrain the growth of the global generic oncology drugs market.

Overall, the global generic oncology drugs market is projected to exhibit significant growth in the coming years, driven by increasing demand for cost-effective cancer treatment options, rising research and development activities, and increasing adoption of advanced technologies.

Generic Oncology Drugs Market Segmentations


Market Breakup by Molecule Type
  • Large Molecule
  • Small Molecule
Market Breakup by Route of Administration
  • Oral
  • Parentals
Market Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Generic Oncology Drugs Market


Some key trends in the generic oncology drugs market are:
  • Increasing prevalence of cancer: As the incidence of cancer continues to rise globally, the demand for effective and affordable treatment options is also increasing. This is driving the growth of the generic oncology drugs market.
  • Growing focus on cost containment: With rising healthcare costs, payers and providers are increasingly focused on cost containment measures. Generic drugs offer a more cost-effective alternative to branded drugs, which is driving the growth of the generic oncology drugs market.
  • Patent expirations of branded drugs: The patent expirations of several blockbuster oncology drugs are leading to the entry of generic versions of these drugs. This is creating opportunities for generic drug manufacturers to enter the market and gain market share.
  • Increasing competition among generic drug manufacturers: As more players enter the market, competition among generic drug manufacturers is increasing. This is leading to price erosion, which is a major challenge for companies operating in this market.
  • Growing demand for biosimilars: Biosimilars are gaining traction in the oncology market, as they offer a more affordable alternative to expensive biologics. This is driving the growth of the generic oncology drugs market.

Generic Oncology Drugs Market: Competitor Landscape


The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Merk & Company, Inc.
  • Aurobindo Pharma.
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • NATCO Pharma Limited
  • CELGENE CORPORATION
*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Generic Oncology Drugs Market Overview
6.1 Global Generic Oncology Drugs Market Historical Value (2016-2022)
6.2 Global Generic Oncology Drugs Market Forecast Value (2023-2031)
7 Global Generic Oncology Drugs Market Landscape
7.1 Global Generic Oncology Drugs Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Generic Oncology Drugs Product Landscape
7.2.1 Analysis by Molecule
7.2.2 Analysis by Route of Administration
7.2.3 Analysis by Distribution Channel
8 Generic Oncology Drug Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Generic Oncology Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Generic Oncology Drugs Market Segmentation
11.1 Global Generic Oncology Drugs Market by Molecule Type
11.1.1 Market Overview
11.1.2 Large Molecule
11.1.3 Small Molecule
11.2 Global Generic Oncology Drugs Market by Route of Administration
11.2.1 Market Overview
11.2.2 Oral
11.2.3 Parentals
11.3 Global Generic Oncology Drugs Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacy
11.3.3 Online Pharmacy
11.3.4 Retail Pharmacy
11.4 Global Generic Oncology Drugs Market by Region
11.4.1 Market Overview
11.4.2 North America
11.4.3 Europe
11.4.4 Asia Pacific
11.4.5 Latin America
11.4.6 Middle East and Africa
12 North America Generic Oncology Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Generic Oncology Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Generic Oncology Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Generic Oncology Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Generic Oncology Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 Novartis AG
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Pfizer Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 GlaxoSmithKline plc
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Teva Pharmaceutical Industries Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Merk & Company, Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Aurobindo Pharma.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Hikma Pharmaceuticals PLC
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Mylan N.V.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 NATCO Pharma Limited
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 CELGENE CORPORATION
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
24 Global Generic Oncology Drugs Market - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings